Nevirapin Axiromed (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Axiromed, is a non‑nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It is used to treat HIV‑1 infection in adults and adolescents, helping to suppress viral replication and improve immune function. Nevirapine belongs to the NNRTI class and works by binding to a specific site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s activity.

GNH USA supplies Nevirapin Axiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapin Axiromed is indicated for the treatment of HIV‑1 infection, targeting the viral replication pathway.

- HIV‑1 infection: reduces viral load and helps restore immune function in adults and adolescents.

Nevirapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild skin redness or itching. - Nausea: upset stomach or feeling of queasiness. - Fatigue: general tiredness or lack of energy. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Hepatotoxicity: elevated liver enzymes, jaundice, or liver failure. - Hypersensitivity reaction: fever, eosinophilia, and multi‑organ involvement.

When prescribing Nevirapin Axiromed, clinicians should observe several safety measures to minimise risk.

- Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess for rash: examine patients regularly for signs of severe skin reactions. - Avoid in known hypersensitivity: discontinue if allergic response occurs. - Use caution in pregnancy: consider potential hepatic toxicity and discuss risks with the patient. - Store at ambient temperature (below 25°C): keep in the original container, protect from moisture.

Nevirapin Axiromed can interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Ritonavir: potent CYP3A4 inhibition can raise nevirapine levels, heightening hepatotoxic risk. - Efavirenz: combined NNRTIs may lead to reduced efficacy and increased adverse events. - St. John’s wort: strong CYP3A4 induction can markedly lower nevirapine concentrations.

Moderate Interactions (Monitor Closely): - Carbamazepine: enzyme induction may decrease nevirapine exposure, requiring viral load monitoring. - Antacids (aluminum‑magnesium): may reduce oral absorption of nevirapine; separate dosing times. - Methadone: nevirapine may reduce methadone levels, potentially precipitating withdrawal.